Health and Fitness FDA Issues Final Guidance On the Evaluation and Labeling of Abuse-deterrent Opioids by Gary Kopycinski on April 2, 2015 Gary Kopycinski Author More in Health and Fitness: On Hantavirus, Park Forest Officials Urge Caution May 18, 2026 Rep. Kelly Condemns FDA Approval of Flavored E-Cigarettes May 6, 2026 Park Forest Aligns With Illinois Guidance on Childhood Vaccines Amid Federal Changes January 11, 2026 Silver Spring, Maryland–(ENEWSPF)–April 1, 2015. The U.S. Food and Drug Administration today issued a final guidance to assist industry in developing opioid drug products with potentially abuse-deterrent properties.